Logo Image
|Articles|March 15, 2021

Pharmaceutical Technology

  • Pharmaceutical Technology-03-15-2021
  • Volume 2021 eBook
  • Issue 1

Can FDA Reinvent Inspections

Author(s)Agnes Shanley

A plant inspection backlog caused by COVID-19 restrictions threatens innovation and public health. Now pressured to step up on-site inspections, will FDA embrace new methods?

Pressure is mounting on FDA to step up the pace of on-site inspections that were postponed due to COVID-19 safety issues and restrictions. An open question is whether the agency will use new remote auditing technologies to improve its ability to inspect facilities during the COVID-19 pandemic.

Read this article in Pharmaceutical Technology's Regulatory Sourcebook March 2021 eBook.

Article details

Pharmaceutical Technology
eBook: Regulatory Sourcebook, March 2021
March 2021
Pages: 4-5

Citation

When referring to this article, please cite it as A. Shanley, “Can FDA Reinvent Inspections,” Pharmaceutical Technology Regulatory Sourcebook eBook (March 2021).

Articles in this issue

over 5 years ago

It Takes a Bio/Pharma Village

over 5 years ago

Enabling the Virtual Human Through Physiologically-based Pharmacokinetic Modeling

over 5 years ago

Managing the Risk of Nitrosamine Impurities

over 5 years ago

Overcoming Challenges to Biopharmaceutical Development and Manufacture with Science- and Risk-Based Strategies

over 5 years ago

Extrapolating Data from Adult Clinical Trials to Advance Pediatric Drug Development

over 5 years ago

Collaborative Efforts Address Key Data Integrity Challenges

over 5 years ago

FDA 2021 Guidance Agenda Sees Focus on Generics

over 5 years ago

A Real-World Approach to Evaluating Cleanroom Garments

over 5 years ago

Resources, Guidelines, and Guidance Documents Directory

over 5 years ago

Regulatory and Standard Setting Organizations Directory

Related Content